Did You Know...
...that the video game, Pong, was invented by a guy who graduated at the bottom of his engineering class? Nolan Bushnell spent more time running the games at a local amusement park than he did on his studies at the University of Utah. His dreams of working for Disney's amusement empire were dashed when the company wouldn't hire him. Taking a boring job, Nolan daydreamed about electronic versions of popular games. He invented Pong, the first video game, and went on to found Atari Co.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187632 | Sustained-release preparations of quinolone antibiotics The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay. ... | 05/29/2012 |
| 8158149 | Threo-DOPS controlled release formulation The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concent... | 04/17/2012 |
| 8137694 | Immediate release and sustained release ibuprofen dosing regimen A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a sing... | 03/20/2012 |
| 8128958 | Sustained release pharmaceutical composition The present invention provides a sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cm... | 03/06/2012 |
| 8067030 | Controlled release composition and method of producing the same A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. A controlled release composition comprising (1... | 11/29/2011 |
| 8062666 | Extended release compositions comprising as active compound venlafaxine hydrochloride The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the... | 11/22/2011 |
| 8043631 | Tumor targeting drug-loaded particles A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing age... | 10/25/2011 |
| 8025900 | Sustained release composition of protein drug Disclosed is a sustained release composition of a protein drug. The composition comprises a carrier substrate and a protein drug incorporated in the carrier substrate. The carrier substrate is consisting essentially of a hyaluronic acid or its salts, an amino acid, ... | 09/27/2011 |
| 8017149 | Modified release preparations containing oxcarbazepine and derivatives thereof Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal rele... | 09/13/2011 |
| 8012504 | Sustained release of guaifenesin combination drugs The invention relates to a novel pharmaceutical modified release formulation of guaifenesin and dextromethorphan. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic res... | 09/06/2011 |
| 8007827 | Pharmaceutical dosage forms having immediate release and/or controlled release properties The present invention relates generally to pharmaceutical dosage forms comprising: an absorption window active agent; a controlled release component comprising enteric-coated controlled release beads, wherein the enteric-coated release beads comprise at least two pH... | 08/30/2011 |
| 8007826 | Sustained release aminopyridine composition A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet ... | 08/30/2011 |
| 7998506 | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treatin... | 08/16/2011 |
| 7988997 | Rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities A dosage form which is, in particular, sheet-like and rapidly disintegrating or soluble in an aqueous environment for rapid release of active ingredients in the oral cavity, in body orifices or in body cavities, where the dosage form comprises a matrix which compris... | 08/02/2011 |
| 7988998 | Sustained-release tramadol formulations with 24-hour efficacy A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration. ... | 08/02/2011 |
| 7985420 | Sustained release of guaifenesin combination drugs The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and pseudoephedrine. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic res... | 07/26/2011 |
| 7985421 | Sustained release formulations of guaifenesin and additional drug ingredients The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and at least one additional drug ingredient. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, p... | 07/26/2011 |
| 7976870 | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an ex... | 07/12/2011 |
| 7972624 | Method of manufacturing modified release dosage forms In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises 10-100% of a material having a melting point of less than about 100 degrees C. selected from the stamp consisting of thermoplastic polyalkylene oxides, low m... | 07/05/2011 |
| 7968120 | Modified release dosage forms In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises 10-100% of a material having a melting point of less than about 100 degrees C. selected from the stamp consisting of thermoplastic polyalkylene oxides, low m... | 06/28/2011 |
| 7964215 | Delayed release dosage form The present invention is directed to a delayed release pharmaceutical composition in solid dosage form comprising a core comprised of a therapeutically effective amount of drug, e.g., mesalamine, and a pH sensitive coating comprising a mixture of two different pH se... | 06/21/2011 |
| 7955622 | Controlled-release galantamine formulations Controlled-release galantamine formulations, including controlled-release particles, pellets, granules, and spheres are described. Controlled-release particles, pellets, granules, and spheres with immediate release top-coat are also described. Method of preparing su... | 06/07/2011 |
| 7919116 | Controlled release metformin formulations Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period ... | 04/05/2011 |
| 7914818 | Opioid agonist formulations with releasable and sequestered antagonist Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and me... | 03/29/2011 |
| 7906141 | Sustained-release, oral pharmaceutical forms of formulation A sustained-release, oral pharmaceutical formulation of tramadol comprising a compound formed in situ of tramadol or its salt and a pharmaceutically acceptable acidic substance. The compound formed in situ has a desired water solubility. Also provided are methods of... | 03/15/2011 |
| 7897173 | Sustained-release, oral pharmaceutical formulations and methods of making and using same A sustained-release, oral pharmaceutical formulation of tramadol comprising a compound formed in situ of tramadol or a tramadol salt and a pharmaceutically acceptable acidic substance. The compound formed in situ has a desired water solubility. Also provided are met... | 03/01/2011 |
| 7887841 | Chronotherapeutic dosage forms and methods of treatment using chronotherapy A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core. ... | 02/15/2011 |
| 7879353 | Controlled or sustained-release formulation A formulation comprising: a co-polyester comprising (a) the reaction product of a polycondensation polyester and (b) glycolide; wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and ethylene glycol, ... | 02/01/2011 |
| 7871644 | Pharmaceutical composition for oral use with improved absorption The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least th... | 01/18/2011 |
| 7858122 | Extended release formulation of levetiracetam An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, a... | 12/28/2010 |
| 7838032 | Sustained release of guaifenesin The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range... | 11/23/2010 |
| 7820199 | Stable extended release oral dosage composition A film-coated extended release solid oral dosage composition containing a nasal decongestant, pseudoephedrine or salt thereof, e.g., pseudoephedrine sulfate in a core effective to provide a geometric maximum plasma concentration of pseudoephedrine of about 345 ng/mL... | 10/26/2010 |
| 7794750 | Controlled-release formulations, method of manufacture, and use thereof The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt or solvate thereof, an ionic non-gelling matrix polymer, and a pH modifi... | 09/14/2010 |
| 7794749 | Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity The present invention relates to a dietary supplement and method for a rapidly dissolving and disintegrating solid oral dosage form. Specifically, the present invention provides dietary supplements and methods for the delivery of dietary supplements comprising Argin... | 09/14/2010 |
| 7785625 | Lipophilic-coated microparticle containing a protein drug and formulation comprising same A solid lipophilic microparticle having an average particle size ranging from 0.1 to 200 μm, comprising a lipophilic substance, hyaluronic acid or an inorganic salt thereof and an active ingredient selected from the group consisting of a protein or peptide drug, re... | 08/31/2010 |
| 7780986 | Method of preparing sustained-release preparations of quinolone antibiotics The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay. ... | 08/24/2010 |
| 7771746 | Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof A method of improving bioavailability of ergot derivatives administered using sustained-release delivery systems includes combining an ergot derivative or mixture thereof with a pharmaceutically acceptable hydrophilic swelling agent or mixture thereof and one or mor... | 08/10/2010 |
| 7767227 | Galenical form for oral administration with prolonged release of molsidomine The present invention relates to a novel sustained-release oral galenical form of molsidomine for the treatment of all forms of angina attack (angina of effort, spastic angina, mixed angina). According to the invention, this novel galenical form contains a therapeut... | 08/03/2010 |
| 7749537 | Method of forming a tablet A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, r... | 07/06/2010 |
| 7722898 | Modified-release preparations containing oxcarbazepine and derivatives thereof Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal relea... | 05/25/2010 |
